STOCKHOLM, September 28, 2016. Moberg Pharma AB (OMX: MOB) today announced that patient enrollment has started in U.S., Canada and Germany in the Phase 3 program investigating MOB-015 for the treatment of onychomycosis. MOB-015 is being evaluated over 52 weeks in two randomized, multicenter, controlled Phase 3 studies. The primary endpoint in both studies is the proportion of patients achieving complete cure of their target nail. In total, approximately 700 patients are expected to be enrolled in the two studies. In addition to the previously announced approvals of a North American Phase 3 study from the FDA and Health Canada, a European Phase 3 study was recently approved by the regulatory authority in Germany. Moberg Pharma is also expecting approval from the Polish authorities. “The start of the patient enrollment in the Phase 3 program for MOB-015 is a major milestone for Moberg Pharma,” said Peter Wolpert, CEO of Moberg Pharma. “Our long-term vision is to become a global leader in onychomycosis and we believe that MOB-015 has the potential to establish a new standard of care. The Phase 3 studies have been designed to support registration in North America, Europe and other major markets.” About this information This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 CET on September 28, 2016. About MOB-015 and Onychomycosis Approximately 10% of the general population suffer from onychomycosis and a majority of those afflicted go untreated. The prescription market is growing rapidly after the recent introduction of new topical treatments in North America and Japan. Moberg Pharma expects the U.S. market alone to exceed $2 billion by 2020 and estimates the peak sales potential for MOB-015 to be in the range of $250-$500 million. MOB-015 is an internally developed topical formulation of terbinafine building on Moberg Pharma’s experience from its leading OTC product Kerasal Nail®. Oral terbinafine is the gold standard for treating onychomycosis, but associated with safety issues including drug interactions and liver damage. For many years, developing a topical terbinafine treatment without the safety issues of oral terbinafine has been highly desirable, but unsuccessful due to insufficient delivery of the active substance through the nail. In a previous phase 2 study, MOB-015 demonstrated delivery of high microgram levels of terbinafine into the nail and through the nail plate into the nail bed. Mycological cure of 54% and significant clear nail growth was observed in patients who completed the phase 2 study. The results are remarkable, particularly when taking into account the severity of the nails included in the study – on average approximately 60% of the nail plate was affected by the infection. Plasma levels of terbinafine with MOB-015 were substantially lower than after oral administration, reducing the risk of liver toxicities observed with oral terbinafine. For additional information contact: Peter Wolpert, CEO, Phone: +46 707 35 71 35, E-mail: peter.wolpert@mobergpharma.se Kjell Rensfeldt, VP R&D, Phone: +46 707 12 4532, E-mail: kjell.rensfeldt@mobergpharma.se About Moberg Pharma, www.mobergpharma.com Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, NewSkin®, Domeboro®, Fiber Choice®and PediaCare®. Kerasal Nail®(Emtrix®or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focuses on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).
Moberg Pharma begins patient enrollment in North America
Top 10 Most Recent News Articles
Masimo's smartSET™ Revolutionizes Patient Monitoring
Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...
Continue Reading
LG OLED evo W6: UAE Roadshow Starts with a Bang
They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...
Continue Reading
Hyliion Class Action Deadline Nears for Investors
Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...
Continue Reading
Voter Events by Valley Community Healthcare Aim to Empower
Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....
Continue Reading
Innventure Faces Major Lawsuit Over Misleading Investors
Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...
Continue Reading
Weifang's Cultural Resurgence: A Global Epigraphy Fest
A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...
Continue Reading
AEVEX Facing Class Action Deadline Amid Stock Turmoil
Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...
Continue ReadingTop 5 Most Recently Viewed Articles
Genesis Showcases Innovative GV70 SUV Lineup for 2026
Genesis Showcases Innovative GV70 and Electrified GV70 SUVs Genesis has recently unveiled the redesigned 2026 GV70 and its electric counterpart, the Electrified GV70. These SUVs are set to hit the North American market in 2025, promising an exciting addition to the luxury SUV segment. Key Features and Upgrades The newly designed GV70 and Electrified GV70 boast modern...
Continue Reading
Investors at Risk: Elevance Health Securities Fraud Case Insight
Understanding the Securities Fraud Case Against Elevance Health, Inc. Investors who bought shares in Elevance Health, Inc. (NYSE: ELV) and faced significant financial losses have an important opportunity. A securities fraud lawsuit has been initiated, allowing affected investors to join a class action seeking justice and financial recovery. Details of the Class Action...
Continue Reading
Investors Urged to Join StubHub Class Action for Loss Recovery
Class Action Lawsuit Opportunity for StubHub Investors With issues arising from StubHub Holdings, Inc., investors are now given a vital opportunity to act. If you purchased StubHub shares during its initial public offering (IPO), it’s essential to be aware of the class action lawsuit underway concerning the company's financial disclosures. The lawsuit, titled Salabaj v....
Continue Reading
Exploring the Future of Nabors Industries Amid Earnings News
An Insight into Nabors Industries Earnings Release Nabors Industries (NYSE: NBR) is set to reveal its quarterly earnings report soon. With anticipation building around this significant event, investor interest is at an all-time high as they look forward to the company's performance insights. Analysts are projecting an earnings per share (EPS) of $-1.73. This figure has...
Continue Reading
Andy Garcia's Show to Feature Ethical Family Building Practices
Highlighting Ethical Surrogacy on All Access with Andy Garcia An upcoming segment will emphasize the intersection of reproductive technology and advocacy, which is essential for creating modern families. Educational Insights into Surrogacy and Reproductive Choices The renowned series 'All Access with Andy Garcia' has teamed up with Simple Surrogacy, LLC, to present an...
Continue Reading